Literature DB >> 32425302

Perioperative Outcomes of Urological Surgery in Patients with SARS-CoV-2 Infection.

Aoibhinn McDermott1, John O'Kelly1, Eoghan de Barra2, Fidelma Fitzpatrick3, Dilly M Little1, Niall F Davis4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32425302      PMCID: PMC7229918          DOI: 10.1016/j.eururo.2020.05.012

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


× No keyword cloud information.
The global incidence of severe acute respiratory virus coronavirus 2 (SARS-CoV-2) infection continues to increase daily. To date, many urological centres have prioritised their patients for urgent surgical intervention because of a reduction in operating theatre availability and the risk of hospital-acquired SARS-CoV-2 infection [1], [2]. The first confirmed case of SARS-CoV-2 infection in the Republic of Ireland was diagnosed on February 29, 2020 and as of May 8, 2020, there have been 22 385 confirmed COVID-19 cases, which represents a case rate of 453.3 per 100 000 population [3]. Here we present our perioperative outcomes for patients undergoing urological surgery during the initial stage of the SARS-CoV-2 pandemic in Ireland (between March 16 and May 1, 2020, inclusive). Our hospital has an onsite microbiology laboratory that performs daily SARS-CoV-2 real-time reverse-transcription polymerase chain reaction testing. Our screening policies for elective and emergency urology patients are detailed in the Supplementary material. During the initial 7-wk period of the SARS-CoV-2 pandemic, 101 urological procedures were performed: 73 urgent elective (age 62 ± 13 yr, and American Society of Anesthesiologists [ASA] score 2.65 ± 0.56) and 32 emergency cases (age 51 ± 20 yr, ASA score 1.68 ± 0.82). Elective surgery was prioritised according to recent European guidelines and patients were then placed on a centralised departmental theatre waiting list [1]. Details on all elective and emergency urological procedures are summarised in Supplementary Table 1 and Supplementary Table 2, respectively. In total, seven patients (7/101, 7%) developed symptoms of SARS-CoV-2 infection during the postoperative period, of whom three male patients (3/101, 3%) were diagnosed with symptomatic SARS-CoV-2 infection. All three SARS-CoV-2–positive patients developed significant postoperative pulmonary complications (Supplementary Fig. 1) and one patient died. The remaining four patients were subsequently diagnosed with pyelonephritis (n = 1) or postoperative atelectasis (n = 3) after a negative SARS-CoV-2 nasopharyngeal swab (Table 1 ).
Table 1

Summary of clinical parameters and clinical course in seven patients with suspected SARS-CoV-2 after urological surgerya.

Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7
GenderMaleMaleMaleFemaleFemaleFemaleMale
Indication for PO SARS-CoV-2 NSPyrexia, dry cough, malaisePyrexia, dry cough, dyspnoeaDry cough, dyspnoea, malaisePyrexia, dry coughPyrexiaPyrexiaPyrexia, dry cough
SARS-CoV-2 DxYesYesYesNo (atelectasis)No (atelectasis)No (pyelonephritis)No (atelectasis)
Positive SARS-CoV-2 NSYesYesNoNoNoNoNo
Age (yr)53826770495677
ProcedureLNTURBTRARPLNCystectomyCystectomyNephroureterectomy
ComorbiditiesHTNHTN, ex-smokerSmokerHTN, provoked DVTThrombophiliaHTNT1DM, HTN
ASA score3322323
BMI (kg/m2)33.629.631.635.534.82533
Time to Dx after surgery (d)1442024262
Onset to Dx (d)3611111
Date of SARS-CoV-2 DxApril 12, 2020April 18, 2020April 9, 2020N/AN/AN/AN/A
ICU support requiredNoNoYesNoNoNoNo
FeverYesYesYesYesYesYesYes
Highest fever (°C)39.14035.538.238.539.138.2
DiarrhoeaNoNoNoNoNoNoNo
Highest CRP (mg/l)269272.9107Not measured282186224
LymphopeniaNoYesNoNoYesYesYes
Elevated sCr (μmol/l)176194161127NoNo258
SARS-CoV-2–related eventsViral pneumonia: bilateral pleural effusions and patchy GGO on CXRViral pneumonia: GGO changes involving all lobes of both lungs on CT, MIOverwhelming ARDS within 4 h of readmissionN/A (atelectasis)N/A (atelectasis)N/AN/A
SARS-CoV-2 treatmentNIV (CPAP/BiPAP)NIV (CPAP/BiPAP)VentilatedN/AN/AN/AN/A
SARS-CoV-2 outcomesDischarged after 27 dCurrent inpatient (20 d after Dx)MortalityN/AN/AN/AN/A

ARDS = acute respiratory distress syndrome; ASA = American Society of Anesthesiologists; BiPAP = bilevel positive airway pressure; BMI = body mass index; CPAP = continuous positive airway pressure; CRP = C-reactive protein; CT = computed tomography; CXR = chest X-ray; DVT = deep vein thrombosis; Dx = diagnosis; GGO = ground glass opacity; HTN = hypertension; ICU = intensive care unit; LN = laparoscopic nephrectomy; MI = myocardial infarction; N/A = not applicable; NIV = noninvasive ventilation; NS = nasopharyngeal swab; PO = postoperative; RARP = robot-assisted radical prostatectomy; sCr = serum creatinine; T1DM = type 1 diabetes mellitus; TURBT = transurethral resection of bladder tumour.

Patients 1 and 2 had a positive PO NS for SARS-CoV-2. Patient 3 had a clinical diagnosis of SARS-CoV-2. Patients 4–7 had one or more symptoms of SARS-CoV-2 and a negative NS for SARS-CoV-2.

Summary of clinical parameters and clinical course in seven patients with suspected SARS-CoV-2 after urological surgerya. ARDS = acute respiratory distress syndrome; ASA = American Society of Anesthesiologists; BiPAP = bilevel positive airway pressure; BMI = body mass index; CPAP = continuous positive airway pressure; CRP = C-reactive protein; CT = computed tomography; CXR = chest X-ray; DVT = deep vein thrombosis; Dx = diagnosis; GGO = ground glass opacity; HTN = hypertension; ICU = intensive care unit; LN = laparoscopic nephrectomy; MI = myocardial infarction; N/A = not applicable; NIV = noninvasive ventilation; NS = nasopharyngeal swab; PO = postoperative; RARP = robot-assisted radical prostatectomy; sCr = serum creatinine; T1DM = type 1 diabetes mellitus; TURBT = transurethral resection of bladder tumour. Patients 1 and 2 had a positive PO NS for SARS-CoV-2. Patient 3 had a clinical diagnosis of SARS-CoV-2. Patients 4–7 had one or more symptoms of SARS-CoV-2 and a negative NS for SARS-CoV-2. Data on the safety of surgical procedures in SARS-CoV-2 hospitals are important so that knowledge can be provided to surgeons on perioperative SARS-CoV-2–related outcomes during the COVID-19 pandemic. At present, various guidelines and opinions on preoperative SARS-CoV-2 screening protocols are available (eg, thorax computed tomography vs nasopharyngeal swab). However, such guidelines are limited by their level of evidence as, to date, they are based on expert opinion without robust prospective data [4]. Our current departmental policy is to perform a screening telephone interview 7 d before surgery and to advise elective patients with asymptomatic COVID-19 to self-isolate. A second screening telephone interview in conjunction with a nasopharyngeal swab is carried out 24–48 h before all elective surgery cases. Our short-term findings demonstrate that the incidence and mortality rate of symptomatic SARS-CoV-2 infection is approximately 3% and 1%, respectively, among patients undergoing urological surgery during the pandemic. Diagnosis of postoperative SARS-CoV-2 infection is difficult, as symptoms mimic common postoperative surgical complications (eg, atelectasis). Patients who experience postoperative COVID-19 are likely to develop significant respiratory complications and have a prolonged inpatient admission. Information from this study will enable surgeons to balance the risk of delaying urgent surgical procedures against the increased morbidity and mortality associated with SARS-CoV-2 infection. The authors have nothing to disclose.
  2 in total

1.  Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic.

Authors:  Kristian D Stensland; Todd M Morgan; Alireza Moinzadeh; Cheryl T Lee; Alberto Briganti; James W F Catto; David Canes
Journal:  Eur Urol       Date:  2020-04-09       Impact factor: 20.096

Review 2.  Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres.

Authors:  Riccardo Campi; Daniele Amparore; Umberto Capitanio; Enrico Checcucci; Andrea Salonia; Cristian Fiori; Andrea Minervini; Alberto Briganti; Marco Carini; Francesco Montorsi; Sergio Serni; Francesco Porpiglia
Journal:  Eur Urol       Date:  2020-04-11       Impact factor: 20.096

  2 in total
  7 in total

1.  Analysis of patient outcomes after urological surgery during the second and third waves of SARS-CoV-2 pandemic in a high incidence area.

Authors:  A González-Díaz; J Gil-Moradillo; N Rosillo-Ramírez; C Varela-Rodríguez; A Rodríguez-Antolín; Á Tejido-Sánchez
Journal:  J Healthc Qual Res       Date:  2022-05-05

2.  Robotic surgery can be safely performed for patients and healthcare workers during COVID-19 pandemic.

Authors:  Peter Sparwasser; Maximillian P Brandt; Maximillian Haack; Robert Dotzauer; Katharina Boehm; Mohammed Kamal Gheith; Rene Mager; Wolfgang Jäger; Alexander Ziebart; Thomas Höfner; Igor Tsaur; Axel Haferkamp; Hendrik Borgmann
Journal:  Int J Med Robot       Date:  2021-06-03       Impact factor: 2.483

3.  Urological surgery during SARS-CoV-2 pandemic. Descriptive analysis of the experience in a Urology Department across the pandemic phases.

Authors:  A González-Díaz; P Abad-López; E Peña-Vallejo; M P Caro-González; C Calzas-Montalvo; J Gil-Moradillo; N Miranda-Utrera; J Díez-Sebastián; C Varela-Rodríguez; A Rodríguez-Antolín; A Tejido-Sánchez
Journal:  Actas Urol Esp (Engl Ed)       Date:  2020-09-29

Review 4.  [Urologic cancer care during the first wave of the COVID-19 pandemic : Role of federal cancer registration in Germany].

Authors:  C Bolenz; T Vogel; P Morakis; R Mayr; M Marx; M Burger
Journal:  Urologe A       Date:  2021-02-09       Impact factor: 0.639

5.  Morbidity and Mortality in Patients with Perioperative COVID-19 Infection: Prospective Cohort in General, Gastroesophagic, Hepatobiliary, and Colorectal Surgery.

Authors:  Martin Inzunza; Cecilia Romero; María Jesús Irarrázaval; Magdalena Ruiz-Esquide; Pablo Achurra; Nicolás Quezada; Fernando Crovari; Rodrigo Muñoz
Journal:  World J Surg       Date:  2021-03-21       Impact factor: 3.352

6.  Safety of Bariatric Surgery During the Opening Phase After the First Wave of the COVID-19 Pandemic: Experience at an Academic Center.

Authors:  Fernando Crovari; Martin Inzunza; María J Irarrázaval; Cecilia Romero; Pablo Achurra; Nicolás Quezada; Mauricio Gabrielli; Rodrigo Muñoz
Journal:  Obes Surg       Date:  2021-09-04       Impact factor: 4.129

7.  Results of COVID-minimal Surgical Pathway During Surge-phase of COVID-19 Pandemic.

Authors:  Daniel J Boffa; Benjamin L Judson; Kevin G Billingsley; Erin Del Rossi; Kasey Hindinger; Samantha Walters; Theresa Ermer; Elena Ratner; Marci R Mitchell; Maxwell S Laurans; Dirk C Johnson; Peter S Yoo; John M Morton; Holly B Zurich; Kimberly Davis; Nita Ahuja
Journal:  Ann Surg       Date:  2020-12       Impact factor: 12.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.